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Background: To evaluate efficacy in patients with brain metastasis (BM) on entry into the lapatinib expanded
access program (LEAP).
Methods: LEAP is a worldwide, single-arm, open-label study. HER2-positive, locally-advanced or metastatic breast
cancer patients with progression after an anthracycline, taxane, and trastuzumab were eligible. Patients received
capecitabine 2000 mg/m2 daily in two divided doses, days 1–14, every 21 days and lapatinib 1250 mg once daily.
Results: Among 186 patients enrolled in 6 Korean centers, 58 had BM. Progression-free survival (PFS) was
18.7 weeks in patients with BM and 19.4 weeks without BM (P = 0.88). In patients with BM, brain response was
synchronized with systemic responses (P = 0.0001). Overall survival (OS) was 48.9 weeks in patients with BM and
64.6 weeks without BM (P = 0.23). Multivariable analysis found hormone receptor positivity (P = 0.003) and clinical
benefit rate (CBR) of combined systemic and brain disease (P< 0.0001) significantly associated with prolonged brain
PFS, and CBR of combined systemic and brain disease (P = 0.03) and longer trastuzumab use (P = 0.047) associated
with prolonged OS in patients with BM; prior capecitabine did not affect PFS or OS in patients with BM.
Conclusion: Lapatinib plus capecitabine is equally effective in patients with or without BM.
Trial registration: ClinicalTrials.gov (NCT00338247)
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Patients with HER2-positive breast cancer who have been
treated with trastuzumab are at greater risk for develop-
ing brain metastasis, with the incidence ranging from
25% to 36% [1-4]. Therefore, anti-HER2 therapy that has
central nervous system (CNS) activity may decrease its
incidence or benefit these patients as a salvage therapy.
Lapatinib is an oral small molecule tyrosine kinase in-
hibitor that targets epidermal growth factor receptors 1
and 2 (HER2). Lapatinib offers a treatment option for
HER2-positive patients who progress on trastuzumab* Correspondence: jungsro@ncc.re.kr
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reproduction in any medium, provided the orand has been shown to reduce the risk of disease pro-
gression when combined with capecitabine, paclitaxel, or
letrozole in patients with HER2-positive MBC [5-7]. The
registration trial was terminated prematurely after dem-
onstrating a significant benefit in time to progression
(TTP) for lapatinib plus capecitabine versus capecitabine
alone in women with MBC that had been previously
treated with an anthracycline, a taxane, and trastuzumab
(hazard ratio [HR] = 0.51; 95% confidence interval [CI],
0.35 to 0.74; P< 0.001) [5]. An exploratory analysis of
data from the trial showed that fewer patients in the
lapatinib plus capecitabine arm developed new brain
metastases compared to capecitabine alone (2% vs 6%;
P = 0.045) [5,8]. As a small molecule, lapatinib may crossThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activity based on preclinical and clinical evidence [9-11].
In order to accommodate patient demand for lapatinib
after the positive results from the registration trial, two
expanded access studies were initiated: Lapatinib Expanded
Access Program (LEAP) and French Authorisation Tem-
poraire d’Utilisation (ATU) [12-14]. Certain patients were
included in LEAP that would have been excluded from the
registration study, including patients with symptomatic
brain metastases and those with prior capecitabine expos-
ure [5]. Therefore, data from LEAP augments the informa-
tion available from the registration trial.
The current report focuses on clinical efficacy out-
comes data from Korean patients with brain metastasis
who were treated in LEAP.
Methods
Full details of the LEAP study design have been previ-
ously described [12]. Briefly, LEAP is a single-arm,
open-label, expanded access study that enrolled
patients worldwide, including 6 centers in Korea. En-
rollment in Korea commenced January 2007 and con-
cluded April 2008.
Patients aged≥ 18 years with HER2-positive, locally
advanced or metastatic breast cancer were eligible if their
cancer had progressed after treatment with an anthracy-
cline, a taxane, and trastuzumab given alone or in com-
bination in either the metastatic or adjuvant setting.
HER2 status was assessed locally. Additionally patients
with non-measurable disease, ECOG performance status
2, and prior capecitabine therapy were included. Patients
with CNS metastases were eligible if steroid requirement
was minimal regardless of CNS symptoms.
Patients received capecitabine 2000 mg/m2 per day in
two divided doses, days 1 to 14, every 21 days and lapa-
tinib 1250 mg once daily. Physicians could delay or ad-
just dosages of either medication for associated
toxicities. Efficacy assessments occurred at 6-week
intervals. Response and disease progression were inves-
tigator assessed according to modified Response Evalu-
ation Criteria in Solid Tumors (RECIST version 1.0)
criteria [15]. For brain metastasis, magnetic resonance
imaging (MRI) reports by the participating centers were
retrospectively interpreted as follows: complete re-
sponse (CR) when the tumor disappeared completely;
partial response (PR) when the tumor shrank by more
than 30% of the longest diameter; any response when
the reports described any degree of response or
decreased size without mentioning tumor dimension;
stable disease (SD) when the tumor did not change in
size; and progressive disease (PD) when the reports
described any degree of increase.
Analyses for progression-free survival (PFS) and over-
all survival (OS) were performed using Kaplan-Meiersurvival analysis. Progression-free survival is calculated
from the administration date of study drug until PD or
death from any cause. An exploratory analysis for
patients with brain metastasis on study entry was per-
formed using the same methods. Brain PFS was analyzed
and calculated from the beginning of study drug to the
date of PD in the metastatic brain tumors. Multivariable
analyses were conducted using Cox’s proportional
hazards model.
Each patient provided written informed consent and par-
ticipating institutional review boards approved the study.
Financial support was provided by GlaxoSmithKline. The
study is registered at ClinicalTrials.gov (NCT00338247).
Results
Patients with brain metastasis
Of a total 186 patients, 58 had brain metastasis on entry.
All patients but one had HER2-positive breast cancer
defined as 3+ immunohistochemistry or gene amplifica-
tion by fluorescence in situ hybridization. Twenty eight
patients (48.3%) were estrogen receptor (ER) and/or pro-
gesterone receptor (PR) positive. Baseline characteristics
are shown in Table 1. Compared to patients without brain
metastasis, those with brain metastasis had a longer me-
dian duration of prior trastuzumab therapy (35.4 weeks vs
20.6 weeks; P = 0.02). Prior to LEAP enrollment, local
treatment of brain metastasis included whole brain radi-
ation (n= 35), stereotactic radiosurgery or gamma-knife
surgery (n= 10), surgical excision (n= 3), and intrathecal
therapy for leptomeningeal disease (n= 1). Four patients
underwent more than one modality and six patients did
not receive local CNS therapy. The median duration of
study drug treatment was similar between patients with
and without brain metastasis (18.6 weeks vs 19.1 weeks,
respectively; P = 0.78).
Efficacy
While central review of MRI was not feasible, we con-
strued response from the serial MRI reports, which were
read by independent radiologists from each center.
Five of 58 patients did not have repeat brain MRIs ever
or upon ending study drugs, including one consent with-
drawal. In an additional patient, brain MRI was taken long
after ending study drugs. Another patient achieved sys-
temic PR but the treating physician did not repeat brain
MRI until brain symptoms occurred after ending study
drugs. There were 4 patients who entered study after
complete surgical excision of BM (n=3) and gamma knife
surgery (n=1). Because of the possibility that these 4
patients (Table 2, Case No.: 8–11) with no evidence of dis-
ease may have artificially influenced the brain PFS, we
checked for the heterogeneity in brain PFS among patients
grouped by their treatment before entering the study (no
local treatment vs surgical or local radiotherapy vs whole
Table 1 Baseline patient characteristics
bb Lapatinib + Capecitabine
Characteristic Brain metastasis
(n = 58)
No Brain metastasis
(n = 128)
P valuea No Prior capecitabine
(n = 95)
Prior capecitabine
(n = 91)
P valuea Total (n = 186†)
No. % No. % No. % No. % No. %
Median age, yrs (range) 46.5 (27-70) 49 (27-71) 0.170 48 (27-71) 47 (29-70) 0.960 48 (27-71)
<50 38 (65.5) 67 (52.3) 0.1111 53 (55.8) 52 (57.1) 0.8832 105 (56.2)
≥50 20 (34.5) 61 (47.7) 42 (44.2) 39 (42.9) 82 (43.9)
Hormone receptor
ER + and/or PR+ 28 (49.1) 45 (35.4) 0.103 36 (38.3) 37 (41.1) 0.764 73 (39.7)
ER- and PR- 29 (50.9) 82 (64.6) 58 (61.7) 53 (58.9) 111 (60.3)
Unknown 1 (1.7) 1 (0.8) 1 (1.0) 1 (1.1) 2 (1.1)
No. metastatic sites
1 5 (8.9) 17 (13.6) 0.174 14 (15.2) 8 (9.0) 0.042 22 (12.2)
2 15 (26.8) 47 (37.6) 37 (40.2) 25 (28.1) 62 (34.3)
≥ 3 36 (64.3) 61 (48.8) 41 (44.6) 56 (62.9) 97 (53.6)
Unknown 2 (3.4) 3 (2.3) 3 (3.2) 2 (2.2) 5 (2.7)
Pattern of metastasis
Visceral only 18 (31.6) 56 (45.5) 0.161 34 (37.8) 40 (44.4) 0.617 74 (41.1)
Non-visceral only 8 (14.0) 11 (8.9) 11 (12.2) 8 (8.9) 19 (10.6)
Both 31 (54.4) 56 (45.5) 45 (50.0) 42 (46.7) 87 (48.3)
Unknown 1 (1.7) 5 (3.9) 5 (5.3) 1 (1.1) 6 (3.2)
Prior capecitabine b 30 (51.7) 61 (47.7) 0 (0.0) 91 (48.9) 91 (48.9)
> 3 Prior chemotherapy regimens 22 (37.9) 45 (35.2) 10 (10.5) 57 (62.6) 67 (36.0)
Median duration of
trastuzumab, wks (range)
35.4 (4.0-113.6) 20.6 (0.1-105.0) 0.016 27.3 (0.1-104.4) 21.6 (3.0-113.6) 0.252 24.1 (0.1-113.6)
Interval from last dose of trastuzumab prior to study entry, wks
Median (range) 11.6 (2.7-146.6) 20.9 (0.1-172.3) 0.365 7.7 (0.1-172.3) 24.9 (1.4-160.9) 0.001 14.6 (0.1-172.3)
< 4 3 (5.2) 16 (12.6) 0.341 14 (14.7) 5 (5.6) <0.001 19 (10.3)
4 - 8 17 (29.3) 33 (26.0) 37 (39.0) 13 (14.4) 50 (27.0)
>8 38 (65.5) 78 (61.4) 44 (46.3) 72 (80.0) 116 (62.7)
Unknown 0 (0.0) 1 (0.8) 0 (0.0) 1 (1.1) 1 (0.5)
a Fisher’s exact χ2 test for categorical variables and independent t-test for continuous variables; two-sided p-values.
b Included 8 cases who had lapatinib during capecitabine.
† Because of few information (only age and study date), 1 patient was excluded.
‘Unknown’ included missing values.
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Table 2 Characteristics of 11 patients with not evaluable or uncertain brain response
Case No Study drug
started
Study drug
ended
Reason for
ending drugs
Best systemic
response
Brain PD by
symptoms
and MRI
Reason for not evaluable brain
response during study period
Inclusion*
1 Consent withdrawal ●
2 2007.3.22 2007.3.29 Unknown Unknown Unknown No follow-up MRI ●
3 2008.2.19 2008.3.11 Unknown Unknown Unknown No follow-up MRI ●
4 2008.2.15 2008.4.1 Systemic PD PD Unknown No follow-up MRI ●
5 2007.3.22 2007.4.17 Systemic PD PD Unknown No follow-up MRI ●
6 2007.8.07 2007.9.17 Systemic PD PD 2008.2.18 MRI long after ending study drug ●, ◊
7 2007.4.02 2008.5.21 Brain PD PR 2008.6.3 No MRI until brain symptoms ●, ◊
8 2007.3.30 2007.6.28 Systemic PD PR 2007.11.12 Metastatectomy prior to study started ◊
9 2007.11.30 2008.2.5 Systemic PD SD< 6mo 2008.7.30 Metastatectomy prior to study started ◊
10 2008.4.8 2008.11.11 Systemic PD SD≥ 6mo 2008.11.7 Metastatectomy prior to study started ◊
11 2007.9.5 2007.12.31 Systemic PD SD< 6mo 2008.2.3 Gamma knife surgery prior to study started ◊
* Included denominator for ●, brain response rate; ◊, brain PFS analysis.
These 11 patients excluded the association between brain response and systemic response (Table 3).
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statistically significant (log-rank test, P = 0.6281) (Table 3).
These four patients remained without evidence of disease
in the brain on study drugs (n=1, Case No 10) or beyond
the end of study drugs (n=3, Case No, 8,9,11) with a me-
dian brain PFS of 31.4 (range, 21.6–34.7) weeks.
Thus, 11 patients were excluded in the analysis of brain
response, but were included in the overall prognosis from
systemic disease and 6 of these patients were included in
brain PFS (Table 2).
Among 47 patients evaluable and 7 patients (Table 2
Case No 1–7) not evaluable for brain response, 2
patients achieved CR, 6 patients achieved PR, and 20
patients experienced some degree of radiologic improve-
ment. Two patients with CR received prior whole brain
radiation. One of these patients showed residual brain
tumors on entry but achieved a CR, documented even in
the last MRI taken a long time after study drug ended,
whose study drugs were discontinued because of sys-
temic PD. The other patient who experienced brain PD
during whole brain radiation, achieved and remained in
CR in both systemic and brain disease until the last
follow-up date on study drugs. We added 7 non-
evaluable patients in the denominator for tumor re-
sponse to lessen the selection bias on the basis of mere
availability of follow-up MRIs. Thus 28 of 54 patients
(51.9%, 95% CI: 38.5–65.2) experienced disease remis-
sion or any degree of tumor shrinkage on LEAP. Stable
disease ≥ 6 months was observed in an additional 8
patients and SD< 6 months was observed in 4 patients;
7 patients developed PD.
To assess the association between the brain and sys-
temic responses, the 11 patients listed in the Table 2
with non-evaluable or uncertain brain response were
excluded. There was a significant association betweenthe brain and systemic responses in patients with BM
(P = 0.0001) (Table 4).
While overall PFS in patients with BM was not statisti-
cally significantly different based on hormone receptor
subsets (HR= 1.02, 95% CI: 0.60-1.74; P = 0.94), brain
PFS was shorter in patients with hormone receptor-
negative disease (HR= 1.78, 95% CI: 1.00-3.19; P = 0.05;
Figure 1).
In the overall population (n = 186), median PFS was
18.7 weeks in patients with BM and 19.4 weeks in
patients without BM (HR 0.98 [95% CI: 0.71-1.35],
P = 0.88). Among patients with BM, median overall PFS
was significantly prolonged in patients who did not use
prior capecitabine (28.3 weeks vs 14.0 weeks, P = 0.009),
but brain PFS was not statistically significantly different
between these two subsets (31.4 weeks vs 25.6 weeks,
P = 0.54; Figure 1).
Combined brain and systemic responses were a signifi-
cant factor for brain PFS (HR=3.65, 95% CI: 1.95-6.85;
P< 0.0001) and OS (HR=2.18, 95% CI: 1.07-4.42; P=0.031)
in both univariate and multivariable analyses (Table 5).
Overall survival among patients with BM was pro-
longed in patients who used trastuzumab longer in the
past (median duration of ≥35.4 weeks,
HR= 0.50, 95% CI: 0.25-0.99; P = 0.047). Of patients
with BM, those with hormone receptor-positive disease
lived longer (median 68.7 weeks vs 42.3 weeks), but the
difference did not reach statistical significance (P = 0.14;
Figure 1).
Reasons for stopping study drugs among patients with
BM were brain PD in 16 patients (29%), systemic PD in
20 patients (36%), both brain and systemic PD in 15
patients (27%) and adverse events in 1 patient (2%).
Three patients (5%) continue to take both study drugs
on study as of the cut-off date, May 20, 2010.
Table 3 Brain PFS Heterogeneity by Treatment Effects using Log-rank test
Best brain
response
CR PR Any Response SD≥ 6mo SD< 6mo PD Total Log-rank test
for treatment,
P-valueTreatment
before entering
the study
No. Median
brain PFS,
wk (95 % CI)
No. Median
brain PFS,
wk (95 % CI)
No. Median
brain PFS,
wk (95 % CI)
No. Median
brain PFS,
wk (95 % CI)
No. Median
brain PFS,
wk (95 % CI)
No. Median
brain PFS,
wk (95 % CI)
No. Median
brain PFS,
wk (95 % CI)
No 0 NE 2 59.3 (NE) 0 NE 1 30.4 (NE) 1 12.6 (NE) 2 9.2 (6.4-12.0) 6 21.5 (12.0-59.3) 0.6281
Excision/GKS/
SRS/FSRT
4 32.4 (21.6-34.7) 0 NE 6 27.5 (20.0-53.7) 2 36.4 (28.1-44.7) 0 NE 0 NE 12 31.4 (22.1-34.7)
WBRT 2 84.3 (NE) 4 21.1 (15.9-NE) 13 40.9 (25.0-59.0) 5 35.0 (26.1-NE) 3 17.9 (12.6-24.0) 5 10.7 (4.0-32.6) 32 31.1 (23.7-41.0)
Subtotal 6 33.6 (30.4-84.3) 6 42.4 (16.6-NE) 19 32.9 (23.7-54.1) 8 33.2 (28.1-48.6) 4 15.2 (12.6-24.0) 7 10.7 (6.4-12.1) 50 30.6 (24.0-34.7)
IT MTX 1 17.0 (NE) 1 17.0 (NE)
Total 6 33.6 (30.4-84.3) 6 42.4 (16.6-NE) 20 32.8 (22.1-54.1) 8 33.2 (28.1-48.6) 4 15.2 (12.6-24.0) 7 10.7 (6.4-12.1) 51 30.4 (23.7-34.7)
CR, complete response; FSRT, fractionated stereotactic radiotherapy; GKS, gamma knife surgery; IT MTX, intrathecal methotrexate; PR, partial response; PD, progressive disease; SD, stable disease; SRS, stereotactic
radio-surgery; WBRT, whole-brain radiotherapy; NE, not estimable.
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Table 4 Association between brain response and systemic response in patients with brain metastasis at study entry
Best Systemic Response Best Brain Response
CR PR Any response SD> 6 m SD< 6 m PD Total P-value*
No (%) No (%) No (%) No (%) No (%) No (%) No (%)
CR 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.0001
PR 1 (50.0) 2 (33.3) 12 (60.0) 2 (25.0) 0 (0.0) 1 (14.3) 18 (38.3)
SD> 6 m 0 (0.0) 0 (0.0) 3 (15.0) 6 (75.0) 1 (25.0) 0 (0.0) 10 (21.3)
SD< 6 m 1 (50.0) 4 (66.7) 3 (15.0) 0 (0.0) 3 (75.0) 2 (28.6) 13 (27.7)
PD 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 4 (57.1) 6 (12.8)
Total 2 (3.7) 6 (11.1) 20 (37.0) 8 (14.8) 4 (7.4) 7 (13.0) 47 (100.0)
* The patients with evaluable response were calculated by Fisher’s exact test.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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Baseline characteristics for the overall population are
shown in Table 1. Two patients with HER2-negative or
unknown status were included in the study. Patients
with prior capecitabine harbored a greater number of
metastatic sites (P = 0.04). The proportion of patients
with ≥ 3 metastatic sites was 62.9% among those with
prior capecitabine compared to 44.6% among those
without prior capecitabine. The median interval between
the last dose of trastuzumab and study entry was longer
among patients with prior capecitabine exposure
(24.9 weeks vs 7.7 weeks; P = 0.001). The median dur-
ation of study drug treatment for all patients wasA B
D E
Figure 1 Kaplan-Meier estimates for (A) brain PFS by hormone recept
by hormone receptor (HR) status; (D) brain PFS by prior capecitabine
patients with brain metastasis on entry.19 weeks (range, 0.14-146.9+) with a significantly longer
duration in patients with no prior capecitabine (median
24 weeks vs 17.9 weeks; P = 0.01).Efficacy
In all patients, the overall response rate was 37.7%, with
a median PFS of 19.4 weeks (95% CI = 18.3-24.0) and
median OS of 59.4 weeks (95% CI = 49.7-68.3). New
brain metastases developed in 8 patients (6.2%) among
the 128 patients without brain metastasis at baseline
during the study. Brain was the only site of disease pro-
gression in six of these patients.C
F
or (HR) status; (B) PFS by hormone receptor (HR) status; (C) OS
; (E) PFS by prior capecitabine; and (F) OS by prior capecitabine in
Table 5 Univariate and multivariable analyses of brain PFS and OS in patients with brain metastasis at baseline (N= 53)
Risk Factor Univariate analysis Multivariable analysisa
Brain PFS OS Brain PFS OS
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Prior capecitabine vs. no prior
capecitabine
1.20 0.68-2.11 0.5377 1.22 0.67-2.22 0.5195
Hormone receptor positive vs.
hormone receptor negative
0.56 0.31 -1.00 0.0507 0.62 0.34-1.13 0.1190 0.38 0.20-0.72 0.0031
Best systemic response SD< 6 m,
PD vs. CR, PR, SD≥ 6 m
2.47 1.39-4.40 0.0022 3.55 1.89-6.67 <0.0001
Median trastuzumab duration,
wks ≥35.4 vs. <35.4
0.85 0.48-1.50 0.5672 0.45 0.24-0.85 0.0140 0.50 0.25-0.99 0.0476
Age at ≥50 vs. <50 0.67 0.36-1.23 0.1925 1.13 0.61-2.13 0.6958
No. of metastasis ≥3 vs. <3 0.81 0.44-1.48 0.4918 1.10 0.57-2.13 0.7733
No. of prior chemotherapy regimens
>3 vs.≤ 3
0.88 0.48-1.61 0.6835 1.48 0.79-2.76 0.2169
Pattern of metastasis Visceral only
vs other
1.51 0.80-2.85 0.1994 1.16 0.58-2.31 0.6778
Median TTbrainP, wks ≥30.7 vs. <30.7 0.44 0.24-0.82 0.0095 0.58 0.29-1.16 0.1223
Median interval from brain metastasis
diagnosis to study enrollment,
wks ≥8.1 vs. <8.1
1.42 0.80-2.53 0.2365 1.49 0.81-2.74 0.2032
Brain response* SD< 6 m, PD vs. CR, PR,
any response, SD≥ 6 m
7.44 3.42-16.18 <0.0001 1.79 0.85-3.77 0.1263
Brain response & systemic response
Else vs . Both of CR, PR, SD≥ 6 m
2.82 1.57-5.09 0.0006 3.16 1.68-5.96 0.0004 3.65 1.95-6.85 <0.0001 2.18 1.07-4.42 0.0311
a Risk factors were determined using univariate Cox’s proportional hazards regression (α <0.10).
* excluded 2patients with not evaluable reponse.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTbrainP, time to brain progression.
HR, hazard ratio; CI, confidence interval.
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observed in patients with no prior capecitabine ex-
posure compared to those with exposure (HR = 1.50,
95% CI: 1.12-2. 02; P = 0.006; Figure 2A). MedianA
E
C
Figure 2 In the overall population regardless of brain metastasis stat
OS by prior capecitabine; (C) PFS by hormone receptor (HR) status; (D
brain metastasis status.PFS was 25.0 weeks in patients without prior capeci-
tabine exposure and 18.0 weeks in patients with ex-
posure. Consistent with these observations, overall
response rates were lower among patients with priorB
D
F
us, Kaplan-Meier estimates for (A) PFS by prior capecitabine; (B)
) OS by HR status; (E) PFS by brain metastasis status in; (F) OS by
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prolonged OS in patients without prior capecitabine was
apparent but not statistically significant (HR=1.33 [95%
CI, 0.97-1.83]; P = 0.08; Figure 2B). Between hormone
receptor-positive and hormone receptor-negative patients
in the overall population, hormone receptor-positive
patients lived longer, but no statistical significance was
observed in PFS (HR=0.78 [95% CI, 0.57-1.06]; P = 0.10;
Figure 2C) or OS (HR=0.80 [95% CI, 0.57-1.11]; P = 0.17;
Figure 2D).
Multivariable analysis failed to reveal a significant
benefit associated with no prior capecitabine for PFS or
OS in the overall population (Table 6). Variables signifi-
cantly associated with prolonged PFS were non-visceral
metastasis, longer prior trastuzumab use, and systemic
response to study drugs. Significant variables for pro-
longed OS were fewer metastatic sites, fewer prior
chemotherapy regimens, longer trastuzumab use, and
longer time to progression.
No significant difference was observed between
patients with or without BM in PFS (HR= 0.98; P = 0.88;
Figure 2E) or OS (HR 1.23; P = 0.23; Figure 2F). As of
the data cut-off date, 48 of 58 patients with brain metas-
tasis (83%) and 105 of 128 patients without brain metas-
tasis (82%) had died.
Discussion
The LEAP study offered the opportunity to evaluate
patients with brain metastases and those with prior cape-
citabine exposure. Data from this study provided evidence
that patients with HER2-positive brain metastasis
achieved a significant clinical benefit from receiving lapati-
nib plus capecitabine therapy. Patients who entered the
study with brain metastasis had similar PFS to those with-
out brain metastasis (median 18.7 weeks vs 19.4 weeks, re-
spectively; P = 0.88) but shorter OS (median 48.9 vs 64.6,
respectively; P = 0.23) without statistical significance. The
similar PFS reflected the efficacy of lapatinib in combin-
ation with capecitabine in the intracranial metastatic
lesions. These data are supported by the phase II study
results by Lin, et al showing that lapatinib with capecita-
bine has activity in CNS metastasis [11]. Among 242
patients with brain metastasis in their series, CNS object-
ive responses to lapatinib were observed in 6% of patients.
However in an exploratory analysis, 21% of patients
experienced a ≥20% volumetric reduction in their CNS
lesions. Of the 50 evaluable patients who entered the lapa-
tinib plus capecitabine extension portion of that study,
20% experienced a CNS objective response and 40%
experienced a ≥20%volumetric reduction in their CNS
lesions. Although they appear similar in response rates be-
tween the studies by extrapolation, we are aware that re-
sponse evaluation may not be the optimal method to
assess the potential anticancer activity in brain tumorlesions as pointed out by Therasse, et al in the RECIST
guidelines [15]. In such cases, PFS can be considered a
valuable alternative to evaluate clinical efficacy [15].
Furthermore, we examined whether the objective
responses and/or decreases in tumor size in the CNS
paralleled those of the extra-CNS disease. Indeed, the
data showed that those who responded in the brain
tended to have systemic response with statistical signifi-
cance (P = 0.0001).
A retrospective analysis of 126 metastatic breast can-
cer patients with brain metastasis revealed prolonged
survival associated with hormone receptor-positive com-
pared to hormone receptor-negative subtype in HER2-
positive disease when measured from the date of
systemic recurrence (median, 27.4 months vs 20.9 months)
or from brain metastasis (median, 9.2 months vs
5.0 months) [16]. Other studies have indicated a poorer
prognosis associated with hormone receptor-negative sub-
type compared to hormone receptor-positive in patients
with HER2-positive MBC not necessarily harboring brain
metastasis [17]. The current study corroborates these data
with a statistically significant prolonged brain PFS in
patients with hormone receptor-positive/HER2-positive
breast cancer compared to the hormone receptor-negative
/HER2-positive subtype. Overall survival was prolonged as
well (HR=1.61) but did not reach statistical significance
in this small population (P= 0.12).
Unlike the lapatinib pivotal trial [5], this study provided
an opportunity to evaluate outcomes in patients accord-
ing to prior capecitabine exposure. Although patients
with brain metastasis without prior capecitabine exposure
achieved longer overall PFS (median; 28.6 weeks vs
14 weeks, P = 0.009), there was no difference in brain PFS
regardless of prior capecitabine use. The majority of the
patients without brain metastasis who had history of dis-
ease progression on prior capecitabine experienced clin-
ical benefit by the reuse of capecitabine in combination
with lapatinib to a certain extent (median TTP 26.9 weeks
without prior capecitabine vs 18.0 weeks with prior cape-
citabine; P = 0.002 ). Moreover, prior capecitabine was not
statistically significantly associated with OS in multivari-
ate analysis. These results are consistent with the analysis
of the worldwide LEAP population, in which median PFS
was 23.9 weeks in patients without prior capecitabine ex-
posure and 18.4 weeks in patients with prior exposure
[12]. This clinical benefit by capecitabine retrial in com-
bination with lapatinib could be partly explained by the
in vitro synergistic cytotoxicity between a lapatinib analog
and the capecitabine metabolite 5'-deoxy-5-fluorouridine
against breast cancer cell lines [18]. Other possible con-
founding factors related with the poorer outcomes in as-
sociation with prior capecitabine therapy were a higher
rate of patients who had received >3 prior chemotherapy
regimens. At baseline, patients with prior capecitabine
Table 6 Univariate and multivariable analysis of PFS and OS in all patients (N= 186)
Risk Factor Univariate analysis Multivariable analysis a
PFS OS PFS OS
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Prior capecitabine vs. no prior capecitabine 1.50 1.12-2.02 0.0072 1.33 0.97-1.83 0.0790 1.22 0.89-1.67 0.2140 0.73 0.48-1.10 0.1351
Hormone receptor positive vs. hormone
receptor negative
0.78 0.57-1.06 0.1064 0.80 0.57-1.11 0.1741
Best systemic response SD, PD vs. CR, PR 2.54 1.85-3.48 <0.0001 1.88 1.33-2.64 0.0003 2.60 1.87-3.63 <0.0001 1.31 0.86-1.99 0.2064
Median prior trastuzumab duration,
wks ≥24.1 vs. <24.1
0.68 0.50-0.91 0.0108 0.57 0.41-0.78 0.0006 0.66 0.48-0.89 0.0074 0.68 0.48-0.96 0.0271
Age ≥50 vs. <50 0.89 0.66-1.20 0.4418 0.84 0.61-1.15 0.2726
No. of metastasis ≥3 vs. <3 1.16 0.86-1.16 0.3427 1.64 1.18-2.28 0.0034 1.78 1.23-2.58 0.0023
No. of prior chemotherapy regimens >3 vs. ≤3 1.17 0.86-1.58 0.3214 1.58 1.14-2.19 0.0067 1.64 1.08-2.47 0.0194
Pattern of metastasis Visceral only vs. other 1.58 1.17-2.15 0.0031 0.98 0.70-1.36 0.8928 1.61 1.18-2.21 0.0031
Median TTP, wks ≥20.0 vs. <20.0 0.36 0.26-0.50 <0.0001 0.37 0.25-0.56 <0.0001
Brain metastasis vs. no brain metastasis 0.98 0.71-1.35 0.8979 1.23 0.88-1.74 0.2310
a Risk factors were determined using univariate Cox’s proportional hazards regression (α <0.10).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTP, time to disease progression.
HR, hazard ratio; CI, confidence interval.
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finding that supports more advanced disease in this
group.
Efficacy outcomes in the overall Korean population
(median PFS, 20 weeks; median survival, 60 weeks) are
consistent with experience with lapatinib plus capecita-
bine in the worldwide LEAP population (median PFS,
21 weeks; median OS, 40 weeks) [12]. Although the
study is limited by a non-randomized design, and a
retrospective evaluation of brain metastasis, this study
provides data on a broader population than was tested
in the lapatinib registration trial and offers specific effi-
cacy information in this selected population who harbor
brain metastasis.
Conclusions
In patients with HER2-positive brain metastasis who
received lapatinib plus capecitabine, combined brain and
systemic responders and patients with hormone
receptor-positive disease achieved prolonged PFS and
those who achieved both brain and systemic responses
and used prior trastuzumab for longer experienced pro-
longed survival. Additionally, the combination of lapati-
nib plus capecitabine in the overall population was
equally effective in patients with or without brain
metastasis.
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